Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

A highly sensitive new blood test can detect rare cancer proteins

Proteins that normally reside inside cell nuclei have never been found in the blood - until now. 

A new blood test developed by Shih-Chin Wang and Chih-Ping Mao - graduate students in Jie Xiao's lab in the Department of Biophysics and Chien-Fu Hung's lab in the Department of Pathology, can identify individual molecules in human blood samples with minimal detection errors down to the sub-femotomolar range.

Among the molecules that they used their new test to find was a mutated protein thought to be restricted to the inside of cells, mostly within the nucleus.

It is the first time that single-molecule imaging has been applied to visualise disease-causing molecules in blood. 

Wang and colleagues call their new approach Single-Molecule Augmented Capture (SMAC).

They used this new technique to detect molecules commonly screened for in standard blood tests, like prostate-specific antigen.

They were also able to detect rare intracellular proteins, secreted proteins and membrane proteins, including the cancer-associated proteins mutant p53, anti-p53 autoantibodies and programmed death-ligand 1 (PD-L1).

Mutant p53 is a well-known tumour-specific nuclear protein and has never before been detected in the blood, likely because current tests cannot detect its extremely low blood concentrations.

Wang and colleagues found mutant p53 or anti-p53 autoantibodies in samples from patients with ovarian cancer, but not in patients without cancer.

PD-L1 is also found on the surface of some cancer cells and has recently been effectively targeted with immunotherapy to combat cancer.

Knowing whether or not a patient's tumour expresses PD-L1 is a crucial first step in this treatment and SMAC may be able to identify cancers that have PD-L1 at low levels that are undetectable by standard blood tests.

"With SMAC, we have brought single-molecule imaging into the clinical arena. By visualising and examining individual molecules released from diseased cells into the blood, we aim to detect diseases more accurately and gain new insights into their mechanisms," Mao explained.

Wang and colleagues are hopeful that their test will one day be commercially available.

Source: Biophysical Society

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation